Table 1 Clinical and demographic characteristics of the participants in this study

From: Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort

Variable

Healthy controls (N=59)

Antipsychotic-naive FEP (N=60)

FEP after treatment (N=60)

p-value

Gender (%)

M:34 (57.6%)

M:40 (66.7%)

 

0.309

Age in years; mean (SD)

25.97 (7.48)

25.63 (7.46)

 

0.808

Currently smoking (%)

N = 2 (3.6%)

N = 12 (23.5%)

 

0.002

Family history of psychosis (%)

 

N = 23 (50%)

  

Cannabis use (%)

 

N = 18 (52.9%)

  

Other drugs use (%)*

 

N = 13 (41.9%)

  

Family income in US$/month (SD)

 

870.59 (792.31)

  

BMI in kg/m2

 

23.58 (3.78)

  

PANSS negative; mean (SD)

 

27.37 (10.51)

25.02 (9.28)

0.127

PANSS disorganization/cognition; mean (SD)

 

26.96 (8.58)

19.91 (6.22)

5.029 × 10-8

PANSS excitement; mean (SD)

 

24.69 (9.09)

13.22 (5.62)

7.84 × 10-14

PANSS positive; mean (SD)

 

34.75 (7.32)

21.23 (9.52)

2.46 × 10-13

PANSS depression/anxiety; mean (SD)

 

24.24 (8.79)

18.11 (7.85)

2.97 × 10-5

PANSS total

 

94.55 (20.94)

68.21 (20.31)

1.71 × 10-10

GAF; mean (SD)

 

31.21 (10.52)

55.47 (16.61)

1.34 × 10-11

CGI; mean (SD)

 

4.83 (0.72)

3.35 (1.26)

1.77 × 10−11

CDSS; mean (SD)

 

4.64 (5.04)

2.48 (4.27)

0.007

  1. M male, SD standard deviation, FEP first-episode psychosis, PANSS Positive and Negative Syndrome Scale, CGI Clinical Global Impression Scale, GAF Global Assessment of Functioning Scale, CDSS Calgary Depression Scale for Schizophrenia
  2. *Drugs including cocaine, sedatives, stimulants, hallucinogens, opioids and gases
Back to article page